Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Erlotinib as Adjuvant Therapy for High-Risk HCC
NCT00293436Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Jan 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib, erlotinib in hepatocellular carcinoma (HCC), sponsored by University of California, San Francisco. Planned start Jan 2005; status: withdrawn.
02
Drugs
celecoxiberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00293436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293436.